TOKYO--(BUSINESS WIRE)--Taiyo Pacific Partners announced today that it has accumulated in excess of 5% in Peptidream, Inc. (4587) to become Peptidream’s second largest institutional shareholder. Peptidream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. Taiyo Pacific Partners is a pioneer of friendly engagement investing in Japan and has been proactively working with senior management at its portfolio companies to enhance shareholder value for over 11 years.
Brian K. Heywood, Chief Executive Officer and Founding Partner of Taiyo Pacific Partners, said, “Peptidream’s innovation in peptide development is a very exciting breakthrough which combines the advantages of both traditional small molecule medicines with those of more expensive antibody pharmaceuticals. We strongly believe they will unlock tremendous value for patients as well as shareholders as they work with the top drug makers around the world in this growing field.”
Help employers find you! Check out all the jobs and post your resume.
Brian K. Heywood, Chief Executive Officer and Founding Partner of Taiyo Pacific Partners, said, “Peptidream’s innovation in peptide development is a very exciting breakthrough which combines the advantages of both traditional small molecule medicines with those of more expensive antibody pharmaceuticals. We strongly believe they will unlock tremendous value for patients as well as shareholders as they work with the top drug makers around the world in this growing field.”
Help employers find you! Check out all the jobs and post your resume.
